Rapport Therapeutics (NASDAQ:RAPP) COO Sells $58,265.02 in Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) COO Cheryl Gault sold 2,014 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $28.93, for a total transaction of $58,265.02. Following the sale, the chief operating officer directly owned 169,914 shares in the company, valued at $4,915,612.02. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Rapport Therapeutics Stock Performance

Shares of Rapport Therapeutics stock opened at $30.54 on Thursday. The company has a 50-day simple moving average of $28.14 and a two-hundred day simple moving average of $26.89. The stock has a market capitalization of $1.46 billion, a PE ratio of -10.68 and a beta of 1.51. Rapport Therapeutics, Inc. has a 52-week low of $7.73 and a 52-week high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). As a group, equities research analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Wells Fargo raised its price target to $46 and kept an “overweight” rating, highlighting upside (~50.6% from the referenced price) and likely contributing to bullish sentiment. Benzinga
• Positive Sentiment: H.C. Wainwright reiterated a Buy and set a $40 price target, citing RAP‑219 program progress and 2026 catalysts — another analyst vote of confidence supporting the rally. TipRanks
• Positive Sentiment: Rapport announced a strategic collaboration and license with Tenacia Biotechnology to develop and commercialize RAP‑219 in Greater China — the deal adds regional commercialization optionality and non‑dilutive funding potential (coverage referenced as a multi‑hundred million biobucks structure). FinanzNachrichten
• Positive Sentiment: Company FYE results and business update: RAP‑219 showed robust Phase 2a activity, Phase 3 initiation is expected in Q2 2026, pipeline expansion (PGTCS, bipolar mania) continues, and cash of ~$490.5M is expected to fund operations into H2 2029 — this reduces financing risk and supports valuation. GlobeNewswire
• Neutral Sentiment: COO Cheryl Gault sold ~2,014 shares (small, ~1.17% reduction of her position) — routine insider selling but disclosed; investors may note timing/size but it’s not large enough to materially change ownership structure. SEC filing
• Negative Sentiment: Reported quarterly EPS of ($0.72) missed consensus of ($0.65), a short‑term negative on earnings momentum that could temper sentiment until Phase 3 execution and trial readouts provide fresh catalysts. Press release / results

Analysts Set New Price Targets

A number of analysts have commented on the company. HC Wainwright lifted their target price on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. BTIG Research raised their price target on shares of Rapport Therapeutics to $47.00 and gave the company a “buy” rating in a report on Monday. The Goldman Sachs Group reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Finally, Wells Fargo & Company boosted their price objective on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a report on Wednesday. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Institutional Trading of Rapport Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its holdings in Rapport Therapeutics by 69.1% in the fourth quarter. Invesco Ltd. now owns 267,120 shares of the company’s stock valued at $8,104,000 after acquiring an additional 109,136 shares during the period. XTX Topco Ltd bought a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $396,000. Vestal Point Capital LP increased its position in shares of Rapport Therapeutics by 16.8% during the 4th quarter. Vestal Point Capital LP now owns 1,110,000 shares of the company’s stock valued at $33,677,000 after purchasing an additional 160,000 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Rapport Therapeutics in the 4th quarter worth approximately $268,000. Finally, Perceptive Advisors LLC boosted its holdings in shares of Rapport Therapeutics by 66.8% in the fourth quarter. Perceptive Advisors LLC now owns 673,923 shares of the company’s stock worth $20,447,000 after buying an additional 270,000 shares during the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.